The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene CD3E (UniProt accession P07766) encodes the T-cell surface glycoprotein CD3 epsilon chain in humans (Homo sapiens). This protein is a critical component of the T-cell receptor (TCR)-CD3 complex and matches the specified UniProt entry, confirming we are investigating the correct gene (mariuzza2020thestructuralbasis pages 2-4, menon2023modulatingtcell pages 2-4).
CD3 epsilon (CD3ε) is a type-I single-pass transmembrane protein that functions as an invariant signaling subunit of the TCR-CD3 complex (chandler2020tcellactivation pages 3-5). The complete TCR-CD3 assembly exhibits a 1:1:1:1 stoichiometry of TCRαβ:CD3γε:CD3δε:CD3ζζ, with CD3ε present in two copies—one paired with CD3γ and one with CD3δ (mariuzza2020thestructuralbasis pages 2-4, mariuzza2020thestructuralbasis pages 1-2).
CD3ε comprises four major structural regions, as detailed in the summary table below:
| Domain/region | Location | Primary function | Key interacting partners or substrates | Clinical/therapeutic relevance |
|---|---|---|---|---|
| Extracellular immunoglobulin-like domain | N-terminal extracellular region of the mature type-I membrane protein | Forms an Ig-like fold and heterodimerizes with either CD3γ or CD3δ; helps assemble, fold, and stabilize the TCR–CD3 complex. Each receptor contains two CD3ε chains—one in CD3γε and one in CD3δε. (xu2020structuralunderstandingof pages 2-3, chandler2020tcellactivation pages 3-5, menon2023modulatingtcell pages 2-4) | CD3γ, CD3δ, and membrane-proximal regions of TCRαβ | Major epitope-bearing region for anti-CD3 antibodies and CD3-engaging bispecifics; therapeutic ligation can activate, redirect, deplete, or tolerize T cells. (menon2023modulatingtcell pages 10-11, menon2023modulatingtcell pages 7-8, menon2023modulatingtcell pages 8-10) |
| Connecting peptide (CP) | Membrane-proximal segment between the extracellular Ig-like domain and transmembrane helix; contains a conserved CxxC motif | Provides conformational linkage between extracellular and transmembrane regions; its intrachain disulfide and contacts support receptor assembly and outside-in signal transmission. (xu2020structuralunderstandingof pages 2-3) | Neighboring TCR/CD3 connecting peptides and extracellular domains | Structural engineering of this region could alter assembly or triggering, but it is not currently an established clinical target. Recent in-situ work indicates extracellular subunit fluidity, rather than large rigid rearrangements, is important for signaling. (natarajan2024insitucellsurface pages 1-2) |
| Transmembrane domain | Single-pass α-helix anchoring CD3ε in the plasma membrane | Acidic and hydrophobic residues participate in an eight-helix TCR–CD3 bundle; electrostatic contacts with basic TCRαβ residues drive assembly and couple antigen recognition to intracellular signaling. (xu2020structuralunderstandingof pages 2-3, mariuzza2020thestructuralbasis pages 2-4) | TCRαβ transmembrane helices and the transmembrane regions of CD3γ or CD3δ | Relevant to engineered control of receptor assembly and allostery; membrane-directed ligands can inhibit proximal TCR phosphorylation, suggesting a possible strategy for autoimmune disease or transplantation. (xu2020structuralunderstandingof pages 2-3, natarajan2024insitucellsurface pages 1-2) |
| Basic residue-rich sequence (BRS) | Membrane-proximal portion of the cytoplasmic tail, upstream of the PRS and ITAM | Binds acidic inner-leaflet phospholipids, reversibly sequestering the tail at the membrane; also recruits LCK and helps position it for CD3-ITAM phosphorylation. (xu2020structuralunderstandingof pages 7-8, xu2020structuralunderstandingof pages 6-7) | Acidic phospholipids and LCK’s unique domain | An engineering module for tuning CAR activation, calcium flux, antigen sensitivity, AKT–mTORC1 signaling, persistence, and cytokine output. (minguet2022harnessingcd3diversity pages 12-14, wu2020multiplesignalingroles pages 14-15) |
| Proline-rich sequence (PRS) | Cytoplasmic tail, between the BRS/di-glycine region and ITAM; normally conformationally cryptic | Becomes accessible during receptor triggering and binds the NCK SH3.1 domain, connecting the TCR to cytoskeletal remodeling, immune-synapse organization, and amplification of proximal signaling. (xu2020structuralunderstandingof pages 7-8) | NCK; cooperative interactions can involve phosphorylated CD3ε and LCK | Candidate motif for tuning synthetic-receptor signaling, although PRS–NCK recruitment was dispensable for cytotoxicity in one CD3ε-based CAR context. (minguet2022harnessingcd3diversity pages 12-14, cardenas2023harnessingcd3diversity pages 1-2) |
| Di-glycine motif | Conserved Gly169–Gly170 in the human precursor sequence, positioned between the BRS and PRS | Appears to provide tail flexibility needed to transmit receptor allostery and expose the PRS. Experimental G169A substitution reduced NCK binding, CD3ε phosphorylation, LCK Ser59 phosphorylation, and phosphorylation of CD3ζ Tyr83. Evidence is from a 2024 preprint and remains provisional. (tercero2024adiglycinemotif pages 1-4, tercero2024adiglycinemotif pages 6-8) | Indirectly regulates NCK, LCK, CD3ζ, ZAP70, LAT, and ERK signaling | Potential synthetic-receptor tuning site and mechanistic disease-variant candidate; no established clinical intervention currently targets it. (tercero2024adiglycinemotif pages 1-4, tercero2024adiglycinemotif pages 6-8) |
| Immunoreceptor tyrosine-based activation motif (ITAM) | C-terminal cytoplasmic motif, consensus YxxL/I–x6–8–YxxL/I; human precursor phosphosites include Tyr188 and Tyr199 | Its two tyrosines are phosphorylated by LCK/FYN after tail exposure, creating a docking site for ZAP70 and initiating calcium, Ras–MAPK, NFAT, NF-κB, and AP-1 signaling. CD3ε contributes one of the ten ITAMs in an αβ TCR–CD3 complex. (menon2023modulatingtcell pages 4-5, chandler2020tcellactivation pages 3-5) | LCK, FYN, ZAP70, and phosphorylation-state-dependent signalosome proteins | Central to anti-CD3 and bispecific-engager activity and an alternative CAR intracellular signaling module. Dynamic phosphorylation is essential: phosphomimetic substitutions disrupted NCK/LCK recruitment and impaired TCR and CAR signaling. (woessner2024phosphomimeticcd3εvariants pages 1-2, cardenas2023harnessingcd3diversity pages 1-2) |
Table: This table maps the principal structural and cytoplasmic signaling regions of human CD3ε to their molecular roles, interaction partners, and translational relevance. Residue numbering explicitly identified in the literature refers to the UniProt precursor sequence where noted.
Extracellular Domain: The N-terminal extracellular region contains an immunoglobulin-like domain that forms heterodimers with either CD3δ or CD3γ through parallel β-strand contacts and side-to-side hydrophobic interactions (xu2020structuralunderstandingof pages 2-3, chandler2020tcellactivation pages 3-5). This domain is essential for assembly and folding of the complete TCR-CD3 complex.
Connecting Peptide: A short membrane-proximal segment containing a conserved CxxC motif forms an intrachain disulfide bond that contributes to TCR-CD3 assembly and outside-in signaling transmission (xu2020structuralunderstandingof pages 2-3).
Transmembrane Domain: The single-pass transmembrane helix participates in an eight-helix bundle formed by all TCR-CD3 components. Acidic residues in CD3ε engage basic lysine and arginine residues of TCRαβ through electrostatic interactions, while hydrophobic contacts stabilize the complex (xu2020structuralunderstandingof pages 2-3, mariuzza2020thestructuralbasis pages 2-4).
Cytoplasmic Tail: The intracellular region contains multiple functional motifs arranged sequentially from membrane-proximal to C-terminal: a basic residue-rich sequence (BRS), a di-glycine motif, a proline-rich sequence (PRS), and an immunoreceptor tyrosine-based activation motif (ITAM) with consensus sequence YxxL/I–x6–8–YxxL/I (xu2020structuralunderstandingof pages 7-8).
Recent cryo-EM structures of the human TCR-CD3 complex resolved the organization of CD3 subunits around the αβTCR, showing that both CD3γε and CD3δε are positioned on the same side of the receptor in both unliganded and peptide-MHC-bound states (natarajan2024insitucellsurface pages 1-2). A 2024 in situ crosslinking study identified an extracellular arrangement of CD3ε′–CD3γ–CD3ε–CD3δ around the αβTCR and demonstrated that the cell-surface complex closely resembles detergent-purified structures (natarajan2024insitucellsurface pages 1-2). Importantly, minimal subunit reorientations occur upon activating antibody or pMHC-tetramer binding, suggesting the absence of large inactive-to-active conformational states in the extracellular regions (natarajan2024insitucellsurface pages 1-2).
A groundbreaking 2024 study identified a highly conserved di-glycine motif (Gly169-Gly170 in human CD3ε) in the cytoplasmic tail, positioned between the BRS and PRS (tercero2024adiglycinemotif pages 1-4). This motif appears critical for transmitting ligand-induced allosteric changes from the TCR to cytoplasmic signaling components. The G169A mutation impaired stimulation-induced Nck binding, reduced CD3ε tyrosine phosphorylation, selectively diminished CD3ζ phosphorylation at Tyr83, and impaired Lck phosphorylation at Ser59 (tercero2024adiglycinemotif pages 1-4, tercero2024adiglycinemotif pages 6-8).
CD3ε functions as a critical signal transduction adaptor rather than a ligand-binding receptor. Its primary role is to convert extracellular TCR engagement into intracellular biochemical signals (menon2023modulatingtcell pages 4-5).
LCK Recruitment: The BRS of CD3ε recruits the Src-family kinase LCK through ionic interactions with LCK's unique domain (xu2020structuralunderstandingof pages 7-8, woessner2024phosphomimeticcd3εvariants pages 1-2, xu2020structuralunderstandingof pages 6-7). LCK can also bind the RK motif within the ITAM region through its SH3 domain, positioning the kinase near the receptor for ITAM phosphorylation (woessner2024phosphomimeticcd3εvariants pages 1-2). This recruitment mechanism is distinctive to CD3ε among CD3 chains and represents a key early event in TCR signaling initiation (xu2020structuralunderstandingof pages 6-7).
NCK Recruitment: The PRS recruits the adaptor protein NCK through NCK's SH3.1 domain (xu2020structuralunderstandingof pages 7-8, woessner2024phosphomimeticcd3εvariants pages 1-2). This interaction becomes accessible following ligand-induced conformational changes that expose the normally cryptic PRS (hartl2020noncanonicalbindingof pages 21-23, woessner2024phosphomimeticcd3εvariants pages 13-13). NCK binding connects the TCR to cytoskeletal recruitment, immunological synapse formation, and amplification of proximal signaling including CD3 ITAM and ZAP70 phosphorylation (xu2020structuralunderstandingof pages 7-8). The NCK-CD3ε interaction is reported to be essential for TCR signaling and immune synapse formation (hartl2020noncanonicalbindingof pages 21-23, tercero2024adiglycinemotif pages 11-14).
CD3ε contains one ITAM that contributes to the total of ten ITAMs in the complete αβ TCR-CD3 complex (CD3γ, CD3δ, and each of the two CD3ε chains contribute one ITAM each, while CD3ζζ contributes six) (menon2023modulatingtcell pages 4-5, chandler2020tcellactivation pages 3-5). Following TCR engagement with cognate peptide-MHC, LCK and FYN phosphorylate tyrosine residues within CD3 ITAMs, creating docking sites for the tandem SH2 domains of ZAP70 (menon2023modulatingtcell pages 4-5, woessner2024phosphomimeticcd3εvariants pages 1-2, chandler2020tcellactivation pages 5-7). This initiates the downstream signaling cascade.
Dynamic phosphorylation of the CD3ε ITAM is essential for proper signaling coordination. Recent 2024 studies using phosphomimetic CD3ε variants demonstrated that irreversible tyrosine phosphorylation prevents signal transduction: Y39E reduced NCK binding, Y50E abolished LCK recruitment while increasing NCK binding, and the double mutation permitted ZAP70 binding but reduced both LCK and NCK interactions (woessner2024phosphomimeticcd3εvariants pages 1-2). These findings emphasize that CD3ε orchestrates optimal TCR signaling through dynamically regulated phosphorylation states rather than through static protein-protein interactions.
CD3ε participates in ligand-induced allosteric changes within the TCR-CD3 complex. In resting T cells, the cytoplasmic domain is held against the plasma membrane through electrostatic interactions between the positively charged BRS and negatively charged phospholipids, sequestering ITAM tyrosines and preventing inappropriate phosphorylation (xu2020structuralunderstandingof pages 6-7, mariuzza2020thestructuralbasis pages 8-9). Following peptide-MHC engagement, CD3ε dissociates from the membrane, exposing signaling regions and permitting kinase access (xu2020structuralunderstandingof pages 7-8, xu2020structuralunderstandingof pages 6-7). This conformational regulation represents a key mechanism for maintaining signaling quiescence in resting cells while enabling rapid activation upon antigen recognition.
CD3ε resides primarily at the T-cell plasma membrane as an integral component of the assembled TCR-CD3 complex (menon2023modulatingtcell pages 4-5, menon2023modulatingtcell pages 2-4). The protein is held within this complex through complementary electrostatic interactions in the transmembrane region, allowing the complete receptor to move laterally through the lipid bilayer as one functional unit (menon2023modulatingtcell pages 4-5, menon2023modulatingtcell pages 2-4).
CD3ε is essential for TCR-CD3 complex assembly and surface expression. It acts as a key chaperone that pairs with both CD3γ and CD3δ to form the CD3γε and CD3δε dimers, which are necessary for proper folding of all CD3 components and thymocyte development (menon2023modulatingtcell pages 4-5). TCR-CD3 assembly proceeds sequentially: TCRαβ first associates with CD3δε, then CD3γε joins, and finally CD3ζζ is incorporated (xu2020structuralunderstandingof pages 2-3). Unpaired or incompletely assembled CD3/TCR subunits are retained in the endoplasmic reticulum and targeted for lysosomal degradation (menon2023modulatingtcell pages 4-5).
A major recent advance reveals that TCR-CD3 signaling is not restricted to the plasma membrane. Following T-cell activation, signaling occurs in specialized intracellular IRAP (insulin-responsive aminopeptidase)/Syntaxin 6-positive endosomal compartments (evnouchidou2020irapdependentendosomalt pages 4-5, evnouchidou2020irapdependentendosomalt pages 2-3, evnouchidou2020irapdependentendosomalt pages 1-2). These vesicles contain multiple TCR signalosome components including ZAP-70, LAT, LCK, CD3ε, and CD3ζ (evnouchidou2020irapdependentendosomalt pages 4-5).
The TCR-CD3ζ complex is internalized through clathrin- and AP2/dynamin-2-dependent endocytosis into these IRAP-containing endosomes, where CD3ζ remains signaling competent (evnouchidou2020irapdependentendosomalt pages 1-2, evnouchidou2020irapdependentendosomalt pages 8-9). IRAP physically associates with CD3ζ and regulates the intracellular availability and signalosome assembly function of this signaling pool (evnouchidou2020irapdependentendosomalt pages 3-4, evnouchidou2020irapdependentendosomalt pages 8-9). Importantly, IRAP's S-acylation is required for its interaction with CD3ζ and for effective TCR signaling (evnouchidou2020irapdependentendosomalt pages 3-4, evnouchidou2020irapdependentendosomalt pages 8-9).
IRAP-positive endosomes polarize toward the immune synapse in antigen-stimulated T cells, and the intracellular CD3ζ pool is recruited continuously to the dynamic synapse (evnouchidou2020irapdependentendosomalt pages 3-4, evnouchidou2020irapdependentendosomalt pages 8-9). This endosomal signaling compartment is particularly important for responses to weak or suboptimal TCR stimulation and contributes to T-cell survival and anti-tumor immunity (evnouchidou2020irapdependentendosomalt pages 8-9, evnouchidou2020irapdependentendosomalt pages 5-6, evnouchidou2020irapdependentendosomalt pages 9-10).
The cytoplasmic domain of CD3ε exhibits dynamic membrane association regulated by calcium and phosphorylation state (xu2020structuralunderstandingof pages 7-8, chandler2020tcellactivation pages 5-7). Calcium-mediated disruption of lipid interactions can provide an additional route to ITAM exposure and can activate bystander TCRs to amplify signaling (xu2020structuralunderstandingof pages 7-8). This regulation is important for both thymocyte development and peripheral T-cell function (xu2020structuralunderstandingof pages 6-7).
CD3ε ITAM phosphorylation initiates a highly orchestrated signaling cascade. Upon peptide-MHC binding and CD3ε membrane dissociation, recruited LCK phosphorylates tyrosine residues within CD3 ITAMs (woessner2024phosphomimeticcd3εvariants pages 1-2, xu2020structuralunderstandingof pages 7-8, xu2020structuralunderstandingof pages 6-7). These phosphorylated ITAMs serve as docking sites for ZAP-70, which is then activated through phosphorylation (menon2023modulatingtcell pages 4-5, woessner2024phosphomimeticcd3εvariants pages 1-2, chandler2020tcellactivation pages 5-7).
Phosphorylated CD3ε participates in cooperative binding of NCK through both its SH3.1 and SH2 domains, with the SH2 domain engaging phosphorylated Tyr177 in the ITAM region (xu2020structuralunderstandingof pages 7-8). This NCK recruitment contributes to cytoskeleton remodeling, immunological synapse formation, and activation of downstream pathways including AKT and ERK1/2 (xu2020structuralunderstandingof pages 7-8).
The CD3ε-initiated signaling cascade propagates through multiple interconnected pathways to activate key transcription factors:
Calcium Signaling: TCR activation triggers Ca²⁺ influx through CRAC channels, and elevated calcium disrupts ionic interactions between CD3 cytoplasmic domains and membrane lipids, exposing additional ITAM tyrosines and amplifying signaling (xu2020structuralunderstandingof pages 7-8). This positive feedback loop enhances T-cell sensitivity.
NFAT, NF-κB, and AP-1 Pathways: CD3 ITAM phosphorylation ultimately activates these three major transcription factor families through production of second messengers Ca²⁺ and IP3 and activation of Ras (menon2023modulatingtcell pages 4-5, woessner2024phosphomimeticcd3εvariants pages 1-2, woessner2024phosphomimeticcd3εvariants pages 13-13). These pathways converge to produce the characteristic transcriptional signature of activated T cells, including cytokine production, proliferation, and effector differentiation.
Co-stimulation Integration: Full T-cell activation requires integration of CD3ε-initiated signals with CD28 co-stimulation, which recruits PI3K, Grb2, Gads, Itk/Tec kinases, LCK, and PKCθ to amplify survival, proliferation, and cytokine-producing pathways (chandler2020tcellactivation pages 5-7).
Recent evidence supports a model in which CD3ε coordinates a regulated sequence of interactions between TCR subunits and associated effector proteins (tercero2024adiglycinemotif pages 1-4). The di-glycine motif appears to facilitate transmission of allosteric changes that sequentially expose or organize binding sites for LCK, NCK, and downstream effectors, while also regulating phosphorylation of CD3ζ at specific tyrosine residues (tercero2024adiglycinemotif pages 1-4, tercero2024adiglycinemotif pages 6-8). This temporal and spatial organization of the signaling cascade represents a sophisticated mechanism for fine-tuning T-cell activation.
CD3ε is absolutely essential for T-cell development and function. CD3ε deficiency results in severe combined immunodeficiency (SCID), characterized by T-cell lymphopenia or absent mature T cells, impaired T-cell activation, and defective mitogenesis (menon2023modulatingtcell pages 4-5). CD3ε-null mice completely lack mature thymocytes, and this developmental block can be rescued by reintroducing a CD3ε transgene (menon2023modulatingtcell pages 4-5). Among CD3 subunit deficiencies, ε, ζ, and δ defects are particularly life-threatening and lethal, representing some of the most severe forms of inherited SCID (menon2023modulatingtcell pages 4-5).
CD3ε serves as a critical target for bispecific T-cell engaging antibodies that redirect cytotoxic T cells toward tumor cells. Blinatumomab, which engages CD3ε and CD19, is FDA-approved for acute lymphoblastic leukemia and represents a major clinical success (menon2023modulatingtcell pages 10-11, menon2023modulatingtcell pages 7-8). This bispecific T-cell engager (BiTE) activates polyclonal T cells against CD19-positive B-cell malignancies while concentrating activation at the tumor site to reduce systemic effects (menon2023modulatingtcell pages 10-11).
Tebentafusp, an engineered TCR-CD3 scFv fusion protein, is approved for HLA-A*02:01-positive metastatic uveal melanoma, where it activates polyclonal T cells against gp100-positive tumor cells and improves survival outcomes (menon2023modulatingtcell pages 10-11, menon2023modulatingtcell pages 7-8).
MP0533, a multispecific CD33×CD123×CD70 CD3-engaging DARPin, represents a next-generation approach for acute myeloid leukemia (AML). This agent is designed to induce selective T-cell-mediated killing of AML leukemic stem cells by requiring coexpression of at least two of three target antigens, thereby improving selectivity and reducing cytokine release compared to single-antigen engagers (bianchi2024thecd33xcd123xcd70multispecific pages 22-23). MP0533 is currently in phase 1 clinical evaluation (bianchi2024thecd33xcd123xcd70multispecific pages 22-23).
Anti-CD3 monoclonal antibodies have diverse clinical applications beyond oncology:
Transplantation: Muromonab (OKT3) was historically used to treat acute cellular rejection after solid organ transplantation, although its strong agonist activity caused cytokine release syndrome and systemic adverse effects (menon2023modulatingtcell pages 8-10).
Autoimmune Disease: Modified anti-CD3 antibodies with reduced agonist activity are being developed for tolerance induction. Teplizumab, an Fc-receptor-nonbinding humanized anti-CD3 antibody, promotes regulatory T-cell responses and received FDA approval to delay onset of type 1 diabetes (menon2023modulatingtcell pages 8-10). Clinical studies demonstrated improved insulin production and metabolic control (menon2023modulatingtcell pages 7-8, menon2023modulatingtcell pages 8-10). Otelixizumab preserved pancreatic beta cells in recently diagnosed type 1 diabetes patients (menon2023modulatingtcell pages 8-10).
Oral administration of anti-CD3 antibodies has shown promise for promoting tolerogenic responses. Oral OKT3 demonstrated safety in hepatitis C nonresponders with increased regulatory T cells and improved liver enzyme levels, as well as regulatory T-cell induction and improved insulin resistance in nonalcoholic steatohepatitis (menon2023modulatingtcell pages 10-11, menon2023modulatingtcell pages 20-21).
Recent research has revolutionized CAR-T cell design by exploring CD3ε as an alternative intracellular signaling domain to the conventional CD3ζ chain. FDA-approved CARs typically combine a costimulatory domain (such as 4-1BB or CD28) with the CD3ζ intracellular domain, which contains three ITAMs (cardenas2023harnessingcd3diversity pages 1-2, minguet2022harnessingcd3diversity pages 1-4).
CD3ε-Based CARs: Systematic engineering of CARs containing CD3δ, CD3ε, or CD3γ cytoplasmic tails revealed that these single-ITAM CD3 chains unexpectedly outperformed conventional CD3ζ CARs in vivo (minguet2022harnessingcd3diversity pages 12-14, cardenas2023harnessingcd3diversity pages 1-2, minguet2022harnessingcd3diversity pages 1-4). The CD3ε intracellular domain showed superior tumor therapy in preclinical models, with transcriptomic and proteomic analyses revealing differences in activation potential, metabolism, and resistance to stimulation-induced dysfunction (cardenas2023harnessingcd3diversity pages 1-2, minguet2022harnessingcd3diversity pages 1-4, minguet2022harnessingcd3diversity pages 9-12).
Mechanistic Optimization: CD3ε-based CARs require careful engineering of signaling motifs. The ITAM, BRS, and RK motifs are important for CAR-T cytotoxicity, activation, calcium flux, and antigen sensitivity, with the BRS and RK motifs recruiting LCK and providing complementary contributions to signaling (minguet2022harnessingcd3diversity pages 12-14). Dimeric CAR designs improved functionality, particularly for CD3ε CARs which showed poor expression as monomers due to endoplasmic reticulum retention signals (cardenas2023harnessingcd3diversity pages 9-10).
Dual CD3ζ/CD3ε CARs: Adding the full CD3ε cytoplasmic domain to CD19 CARs that retain CD3ζ creates a balanced signaling architecture. CD3ε contributes an inhibitory ITAM that recruits the inhibitory kinase CSK, thereby attenuating the CD3ζ/ZAP70/PLCγ1 axis and reducing excessive cytokine release while maintaining cytotoxicity (wu2020multiplesignalingroles pages 9-12, wu2020multiplesignalingroles pages 14-15). Simultaneously, the CD3ε BRS supports AKT-mTORC1 signaling, improving CAR-T persistence (wu2020multiplesignalingroles pages 14-15). This optimization strategy produced better tumor control and survival in xenograft models for both CD19 and mesothelin CARs (wu2020multiplesignalingroles pages 9-12).
A 2023 Nature Immunology study identified the phosphatase SHP-1 as a new CD3δ interaction partner that binds the phosphorylated C-terminal tyrosine of the CD3δ ITAM, attenuating activation signals and potentially preventing exhaustion (cardenas2023harnessingcd3diversity pages 1-2). This finding has implications for understanding how CD3 chain diversity tunes CAR function.
DNA and RNA aptamers targeting CD3ε represent an economical, mass-producible, reversible platform for T-cell modulation. A DNA aptamer selected against human CD3ε displayed low-nanomolar affinity and, after truncation and dimerization, induced CD69 expression in vitro, indicating agonistic T-cell activation (menon2023modulatingtcell pages 11-12). The limited persistence and reversibility of aptamers could help reduce off-target effects compared to antibody-based approaches (menon2023modulatingtcell pages 11-12).
The mechanism of TCR activation remains an area of active investigation. Recent structural and biophysical studies support an allosteric model in which peptide-MHC binding triggers conformational changes that propagate from the TCR extracellular region through the transmembrane domain to the cytoplasmic tails (mariuzza2020thestructuralbasis pages 2-4, mariuzza2020thestructuralbasis pages 8-9). However, 2024 in situ crosslinking data indicate minimal large-scale reorientations in the extracellular CD3 subunits upon activation, suggesting that subtle dynamic changes or transmembrane-localized rearrangements are more important than dramatic conformational shifts (natarajan2024insitucellsurface pages 1-2).
The discovery of the di-glycine motif as a critical flexible hinge in the CD3ε cytoplasmic tail provides new mechanistic insight into how allosteric changes are transmitted to recruit signaling proteins (tercero2024adiglycinemotif pages 1-4). This finding bridges structural and functional models by identifying a specific sequence element that enables conformational adaptability.
The demonstration of IRAP-dependent endosomal TCR signaling represents a paradigm shift in understanding T-cell activation. Rather than viewing endocytosis solely as a mechanism for signal termination, the field now recognizes that internalized TCR-CD3 complexes continue to signal from specialized endosomal platforms that are insulated from plasma membrane phosphatases and may amplify or sustain signaling under suboptimal stimulation conditions (evnouchidou2020irapdependentendosomalt pages 4-5, evnouchidou2020irapdependentendosomalt pages 1-2, evnouchidou2020irapdependentendosomalt pages 8-9). This has important implications for understanding T-cell responses to weak antigens, tumor immunity, and potentially for optimizing adoptive T-cell therapies.
The finding that single-ITAM CD3 chains can outperform the triple-ITAM CD3ζ chain challenges the assumption that more ITAMs necessarily produce stronger or better T-cell activation (cardenas2023harnessingcd3diversity pages 1-2, minguet2022harnessingcd3diversity pages 1-4). Instead, optimal CAR function appears to depend on signal quality, motif composition, and the balance between activating and inhibitory signals. The ability to tune CAR signaling by selecting specific CD3 chain intracellular domains, engineering motif combinations, and incorporating inhibitory modules like CSK-recruiting ITAMs opens new avenues for rational CAR optimization (wu2020multiplesignalingroles pages 9-12, wu2020multiplesignalingroles pages 14-15, cardenas2023harnessingcd3diversity pages 1-2).
Key areas for future investigation include: (1) determining the precise structural rearrangements in the transmembrane and cytoplasmic regions during activation, (2) elucidating the temporal sequence and spatial organization of CD3ε signalosome assembly, (3) understanding how IRAP-dependent endosomal signaling integrates with plasma membrane signaling to determine overall T-cell responses, (4) translating CD3ε mechanistic insights into improved CAR designs with enhanced safety and efficacy profiles, and (5) developing CD3-targeting agents with tunable agonist versus antagonist activity for treating autoimmune disease, preventing transplant rejection, or enhancing anti-tumor immunity.
CD3E encodes the CD3 epsilon chain, an essential signaling component of the T-cell receptor complex in humans. The protein functions as a molecular organizer that couples antigen recognition to intracellular signaling through recruitment of the kinase LCK and the adaptor NCK, ITAM-dependent ZAP-70 activation, and initiation of calcium, NFAT, NF-κB, and MAPK pathways. CD3ε exhibits remarkable structural sophistication, with multiple cytoplasmic motifs (BRS, di-glycine, PRS, ITAM) that coordinate dynamic, allosterically regulated signaling events at both the plasma membrane and in specialized IRAP-positive endosomal compartments. CD3ε deficiency causes severe combined immunodeficiency, while CD3ε-targeting therapeutic approaches—including bispecific T-cell engagers, immunomodulatory antibodies, and next-generation CAR-T cells incorporating CD3ε signaling domains—represent major advances in cancer immunotherapy, transplantation, and autoimmune disease treatment. Recent 2023-2024 studies continue to reveal new mechanistic insights into CD3ε function, including the role of the di-glycine motif in allosteric signal transmission and the optimization of CAR designs through CD3 chain diversification.
References
(mariuzza2020thestructuralbasis pages 2-4): Roy A. Mariuzza, Pragati Agnihotri, and John Orban. The structural basis of t-cell receptor (tcr) activation: an enduring enigma. Jan 2020. URL: https://doi.org/10.1016/s0021-9258(17)49904-2, doi:10.1016/s0021-9258(17)49904-2. This article has 357 citations and is from a domain leading peer-reviewed journal.
(menon2023modulatingtcell pages 2-4): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(chandler2020tcellactivation pages 3-5): Nicholas J. Chandler, Melissa J. Call, and Matthew E. Call. T cell activation machinery: form and function in natural and engineered immune receptors. Oct 2020. URL: https://doi.org/10.3390/ijms21197424, doi:10.3390/ijms21197424. This article has 22 citations.
(mariuzza2020thestructuralbasis pages 1-2): Roy A. Mariuzza, Pragati Agnihotri, and John Orban. The structural basis of t-cell receptor (tcr) activation: an enduring enigma. Jan 2020. URL: https://doi.org/10.1016/s0021-9258(17)49904-2, doi:10.1016/s0021-9258(17)49904-2. This article has 357 citations and is from a domain leading peer-reviewed journal.
(xu2020structuralunderstandingof pages 2-3): Xinyi Xu, Hua Li, and Chenqi Xu. Structural understanding of t cell receptor triggering. Cellular & Molecular Immunology, 17:193-202, Feb 2020. URL: https://doi.org/10.1038/s41423-020-0367-1, doi:10.1038/s41423-020-0367-1. This article has 96 citations and is from a peer-reviewed journal.
(menon2023modulatingtcell pages 10-11): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(menon2023modulatingtcell pages 7-8): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(menon2023modulatingtcell pages 8-10): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(natarajan2024insitucellsurface pages 1-2): Aswin Natarajan, Yogambigai Velmurugu, Manuel Becerra Flores, Fatoumatta Dibba, Saikiran Beesam, Sally Kikvadze, Xiaotian Wang, Wenjuan Wang, Tianqi Li, Hye Won Shin, Timothy Cardozo, and Michelle Krogsgaard. In situ cell-surface conformation of the tcr-cd3 signaling complex. EMBO Reports, 25:5719-5742, Nov 2024. URL: https://doi.org/10.1038/s44319-024-00314-3, doi:10.1038/s44319-024-00314-3. This article has 5 citations and is from a highest quality peer-reviewed journal.
(xu2020structuralunderstandingof pages 7-8): Xinyi Xu, Hua Li, and Chenqi Xu. Structural understanding of t cell receptor triggering. Cellular & Molecular Immunology, 17:193-202, Feb 2020. URL: https://doi.org/10.1038/s41423-020-0367-1, doi:10.1038/s41423-020-0367-1. This article has 96 citations and is from a peer-reviewed journal.
(xu2020structuralunderstandingof pages 6-7): Xinyi Xu, Hua Li, and Chenqi Xu. Structural understanding of t cell receptor triggering. Cellular & Molecular Immunology, 17:193-202, Feb 2020. URL: https://doi.org/10.1038/s41423-020-0367-1, doi:10.1038/s41423-020-0367-1. This article has 96 citations and is from a peer-reviewed journal.
(minguet2022harnessingcd3diversity pages 12-14): Susana Minguet, Rubí Velasco Cárdenas, Simon Brandl, Emilia Schlaak, Annabelle Buschky, Timo Peters, Fabian Beier, Bryan Serrels, Sanaz Taromi, Katrin Raute, Simon Hauri, Matthias Gstaiger, Silke Lassman, Johannes Huppa, Melanie Boerries, Geoffroy Andrieux, Bertram Bengsch, and Wolfgang Schamel. Harnessing cd3 diversity to optimise car t cells. Unknown journal, Dec 2022. URL: https://doi.org/10.21203/rs.3.rs-2378631/v1, doi:10.21203/rs.3.rs-2378631/v1.
(wu2020multiplesignalingroles pages 14-15): Wei Wu, Qiuping Zhou, Takeya Masubuchi, Xiaoshan Shi, Hua Li, Xinyi Xu, Min Huang, Li Meng, Xing He, Hengyu Zhu, Shuaixin Gao, Nan Zhang, Ruirui Jing, Jie Sun, Haopeng Wang, Enfu Hui, Catherine Chiulan Wong, and Chenqi Xu. Multiple signaling roles of cd3ε and its application in car-t cell therapy. Cell, 182:855-871.e23, Aug 2020. URL: https://doi.org/10.1016/j.cell.2020.07.018, doi:10.1016/j.cell.2020.07.018. This article has 253 citations and is from a highest quality peer-reviewed journal.
(cardenas2023harnessingcd3diversity pages 1-2): Rubí M.-H. Velasco Cárdenas, Simon M. Brandl, Ana Valeria Meléndez, Alexandra Emilia Schlaak, Annabelle Buschky, Timo Peters, Fabian Beier, Bryan Serrels, Sanaz Taromi, Katrin Raute, Simon Hauri, Matthias Gstaiger, Silke Lassmann, Johannes B. Huppa, Melanie Boerries, Geoffroy Andrieux, Bertram Bengsch, Wolfgang W. Schamel, and Susana Minguet. Harnessing cd3 diversity to optimize car t cells. Nature Immunology, 24(12):2135-2149, Nov 2023. URL: https://doi.org/10.1038/s41590-023-01658-z, doi:10.1038/s41590-023-01658-z. This article has 94 citations and is from a highest quality peer-reviewed journal.
(tercero2024adiglycinemotif pages 1-4): Rut Tercero, Elena R. Bovolenta, Nadia Martín-Blanco, Alice Lombard, and Balbino Alarcón. A di-glycine motif in the cytoplasmic tail of cd3ε required for transmission of allosteric changes in the tcr and full cd3ζ phosphorylation. Unknown journal, Jul 2024. URL: https://doi.org/10.21203/rs.3.rs-4594242/v1, doi:10.21203/rs.3.rs-4594242/v1.
(tercero2024adiglycinemotif pages 6-8): Rut Tercero, Elena R. Bovolenta, Nadia Martín-Blanco, Alice Lombard, and Balbino Alarcón. A di-glycine motif in the cytoplasmic tail of cd3ε required for transmission of allosteric changes in the tcr and full cd3ζ phosphorylation. Unknown journal, Jul 2024. URL: https://doi.org/10.21203/rs.3.rs-4594242/v1, doi:10.21203/rs.3.rs-4594242/v1.
(menon2023modulatingtcell pages 4-5): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(woessner2024phosphomimeticcd3εvariants pages 1-2): Nadine M. Woessner, Simon M. Brandl, Sara Hartmann, Wolfgang W. Schamel, Frederike A. Hartl, and Susana Minguet. Phospho-mimetic cd3ε variants prevent tcr and car signaling. Frontiers in Immunology, May 2024. URL: https://doi.org/10.3389/fimmu.2024.1392933, doi:10.3389/fimmu.2024.1392933. This article has 9 citations and is from a peer-reviewed journal.
(hartl2020noncanonicalbindingof pages 21-23): FA Hartl, E Beck-García, NM Woessner, and LJ Flachsmann. Non-canonical binding of the lck sh3 domain to cd3 redefines initiation of tcr signaling and enhances car function. Unknown journal, 2020.
(woessner2024phosphomimeticcd3εvariants pages 13-13): Nadine M. Woessner, Simon M. Brandl, Sara Hartmann, Wolfgang W. Schamel, Frederike A. Hartl, and Susana Minguet. Phospho-mimetic cd3ε variants prevent tcr and car signaling. Frontiers in Immunology, May 2024. URL: https://doi.org/10.3389/fimmu.2024.1392933, doi:10.3389/fimmu.2024.1392933. This article has 9 citations and is from a peer-reviewed journal.
(tercero2024adiglycinemotif pages 11-14): Rut Tercero, Elena R. Bovolenta, Nadia Martín-Blanco, Alice Lombard, and Balbino Alarcón. A di-glycine motif in the cytoplasmic tail of cd3ε required for transmission of allosteric changes in the tcr and full cd3ζ phosphorylation. Unknown journal, Jul 2024. URL: https://doi.org/10.21203/rs.3.rs-4594242/v1, doi:10.21203/rs.3.rs-4594242/v1.
(chandler2020tcellactivation pages 5-7): Nicholas J. Chandler, Melissa J. Call, and Matthew E. Call. T cell activation machinery: form and function in natural and engineered immune receptors. Oct 2020. URL: https://doi.org/10.3390/ijms21197424, doi:10.3390/ijms21197424. This article has 22 citations.
(mariuzza2020thestructuralbasis pages 8-9): Roy A. Mariuzza, Pragati Agnihotri, and John Orban. The structural basis of t-cell receptor (tcr) activation: an enduring enigma. Jan 2020. URL: https://doi.org/10.1016/s0021-9258(17)49904-2, doi:10.1016/s0021-9258(17)49904-2. This article has 357 citations and is from a domain leading peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 4-5): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 2-3): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 1-2): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 8-9): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 3-4): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 5-6): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(evnouchidou2020irapdependentendosomalt pages 9-10): Irini Evnouchidou, Pascal Chappert, Samira Benadda, Andres Zucchetti, Mirjana Weimershaus, Marcelle Bens, Vivien Caillens, Despoina Koumantou, Sophie Lotersztajn, Peter van Endert, Jean Davoust, Pierre Guermonprez, Claire Hivroz, David A. Gross, and Loredana Saveanu. Irap-dependent endosomal t cell receptor signalling is essential for t cell responses. Nature Communications, Jun 2020. URL: https://doi.org/10.1038/s41467-020-16471-7, doi:10.1038/s41467-020-16471-7. This article has 50 citations and is from a highest quality peer-reviewed journal.
(bianchi2024thecd33xcd123xcd70multispecific pages 22-23): Matteo Bianchi, Christian Reichen, Amelie Croset, Stefanie Fischer, Aline Eggenschwiler, Yvonne Grübler, Rajlakshmi Marpakwar, Thamar Looser, Patricia Spitzli, Christel Herzog, Denis Villemagne, Dieter Schiegg, Liridon Abduli, Chloé Iss, Alexandra Neculcea, Marco Franchini, Tamara Lekishvili, Simone Ragusa, Christof Zitt, Yvonne Kaufmann, Alienor Auge, Martin Hänggi, Waleed Ali, Teresa M. Frasconi, Stephan Wullschleger, Iris Schlegel, Mirela Matzner, Ursina Lüthi, Bernd Schlereth, Keith M. Dawson, Vladimir Kirkin, Adrian F. Ochsenbein, Sebastian Grimm, Nina Reschke, Carsten Riether, Daniel Steiner, Nicolas Leupin, and Anne Goubier. The cd33xcd123xcd70 multispecific cd3-engaging darpin mp0533 induces selective t cell–mediated killing of aml leukemic stem cells. Cancer Immunology Research, 12:921-943, Apr 2024. URL: https://doi.org/10.1158/2326-6066.cir-23-0692, doi:10.1158/2326-6066.cir-23-0692. This article has 16 citations and is from a domain leading peer-reviewed journal.
(menon2023modulatingtcell pages 20-21): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.
(minguet2022harnessingcd3diversity pages 1-4): Susana Minguet, Rubí Velasco Cárdenas, Simon Brandl, Emilia Schlaak, Annabelle Buschky, Timo Peters, Fabian Beier, Bryan Serrels, Sanaz Taromi, Katrin Raute, Simon Hauri, Matthias Gstaiger, Silke Lassman, Johannes Huppa, Melanie Boerries, Geoffroy Andrieux, Bertram Bengsch, and Wolfgang Schamel. Harnessing cd3 diversity to optimise car t cells. Unknown journal, Dec 2022. URL: https://doi.org/10.21203/rs.3.rs-2378631/v1, doi:10.21203/rs.3.rs-2378631/v1.
(minguet2022harnessingcd3diversity pages 9-12): Susana Minguet, Rubí Velasco Cárdenas, Simon Brandl, Emilia Schlaak, Annabelle Buschky, Timo Peters, Fabian Beier, Bryan Serrels, Sanaz Taromi, Katrin Raute, Simon Hauri, Matthias Gstaiger, Silke Lassman, Johannes Huppa, Melanie Boerries, Geoffroy Andrieux, Bertram Bengsch, and Wolfgang Schamel. Harnessing cd3 diversity to optimise car t cells. Unknown journal, Dec 2022. URL: https://doi.org/10.21203/rs.3.rs-2378631/v1, doi:10.21203/rs.3.rs-2378631/v1.
(cardenas2023harnessingcd3diversity pages 9-10): Rubí M.-H. Velasco Cárdenas, Simon M. Brandl, Ana Valeria Meléndez, Alexandra Emilia Schlaak, Annabelle Buschky, Timo Peters, Fabian Beier, Bryan Serrels, Sanaz Taromi, Katrin Raute, Simon Hauri, Matthias Gstaiger, Silke Lassmann, Johannes B. Huppa, Melanie Boerries, Geoffroy Andrieux, Bertram Bengsch, Wolfgang W. Schamel, and Susana Minguet. Harnessing cd3 diversity to optimize car t cells. Nature Immunology, 24(12):2135-2149, Nov 2023. URL: https://doi.org/10.1038/s41590-023-01658-z, doi:10.1038/s41590-023-01658-z. This article has 94 citations and is from a highest quality peer-reviewed journal.
(wu2020multiplesignalingroles pages 9-12): Wei Wu, Qiuping Zhou, Takeya Masubuchi, Xiaoshan Shi, Hua Li, Xinyi Xu, Min Huang, Li Meng, Xing He, Hengyu Zhu, Shuaixin Gao, Nan Zhang, Ruirui Jing, Jie Sun, Haopeng Wang, Enfu Hui, Catherine Chiulan Wong, and Chenqi Xu. Multiple signaling roles of cd3ε and its application in car-t cell therapy. Cell, 182:855-871.e23, Aug 2020. URL: https://doi.org/10.1016/j.cell.2020.07.018, doi:10.1016/j.cell.2020.07.018. This article has 253 citations and is from a highest quality peer-reviewed journal.
(menon2023modulatingtcell pages 11-12): Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, Francesca Nonatelli, Helena Villanueva, Martin Barainka, Angelina Zheleva, Hisse M. van Santen, and Fernando Pastor. Modulating t cell responses by targeting cd3. Cancers, 15:1189, Feb 2023. URL: https://doi.org/10.3390/cancers15041189, doi:10.3390/cancers15041189. This article has 137 citations.